CTIS2023-503539-16-00进行中（未招募）1 期
A Randomized, Open-label, Phase 3 Study of MK-2870 vs Chemotherapy (Docetaxel or Pemetrexed) in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) with EGFR Mutations or Other Genomic Alterations - MK2870-004
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 556
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Histologically- or cytologically-documented advanced (Stage III not eligible for resection or curative radiation) or metastatic non-squamous NSCLC with specific mutations, Have an ECOG performance status of 0 or 1 within 3 days before randomization, Documentation of locally assessed radiological disease progression while on or after last treatment based on Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1, Participants with genome mutations must have received 1 or 2 prior lines of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI), including a third generation TKI for participants with a T790M mutation; and 1 platinum-based therapy after progression on or after EGFR TKI, At least 18 years of age at the time of providing informed consent, Measurable disease per RECIST 1.1 as assessed by the local site investigator, Archival tumor tissue sample or newly obtained core, incisional, or excisional biopsy of a tumor lesion not previously irradiated has been provided, Participants who have AEs due to previous anticancer therapies must have recovered to Grade =1 or baseline, Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received HBV antiviral therapy for at least 4 weeks, and have undetectable HBV viral load prior to randomization, HIV-infected participants must have well controlled HIV on ART
排除标准
- •Has predominantly squamous cell histology NSCLC, Completed palliative radiotherapy within 7 days of the first dose. Participants must have recovered from all radiation-related toxicities and not require corticosteroids, Received radiation therapy to the lung that is >30 Gy within 6 months of the first dose of study intervention, Received prior treatment with a trophoblast cell-surface antigen 2 (TROP2)-targeted antibody-drug conjugate (ADC), Received prior treatment with a topoisomerase I-containing ADC, Has received an investigational agent or has used an investigational device within 4 weeks prior to study intervention administration, Known additional malignancy that is progressing or has required active treatment within the past 3 years, Active infection requiring systemic therapy, History of noninfectious pneumonitis/ILD that required steroids or has current pneumonitis/ILD, Has known active central nervous system metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are clinically stable for at least 2 weeks, and are off steroids 3 days prior to dosing with study medication, HIV-infected participants with a history of Kaposi’s sarcoma and/or Multicentric Castleman’s Disease, Has mixed tumor(s) with small cell elements, Concurrent active Hepatitis B (defined as HBsAg positive and/or detectable HBV DNA) and Hepatitis C virus (defined as anti-HCV Ab positive and detectable HCV RNA) infection, Has active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease, Has Grade =2 peripheral neuropathy, Has history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or corneal disease that prevents/delays corneal healing, Has uncontrolled, significant cardiovascular disease or cerebrovascular disease, Has an EGFR T790M mutation and has not received a third generation EGFR TKI (eg, osimertinib), Received prior systemic anticancer therapy including investigational agents within 4 weeks or 5 half-lives (whichever is shorter) before randomization, Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention
研究者
相似试验
招募中
1 期
A clinical study of MK-2870 and chemotherapy to treat lung cancer (MK-2870-009)on-small Cell Lung Cancer (NSCLC), EGFR-mutatedMedDRA version: 21.1Level: PTClassification code: 10061873Term: Non-small cell lung cancer Class: 100000004864CTIS2023-504910-31-00Merck Sharp & Dohme LLC615
尚未招募
3 期
MK-2870 in Combination with Pembrolizumab Versus Pembrolizumab Alone in Metastatic NSCLC with PD-L1 TPS = 50%D022 Bronchus and lungBronchus and lungD022PER-053-23Merck Sharp & Dohme LLC., (una subsidiaria de Merck & Co. Inc.)
招募中
1 期
A clinical study to compare MK-2870 with pembrolizumab to pembrolizumab alone in people with lung cancer (MK-2870-007)Metastatic non-small cell lung cancer (NSCLC)MedDRA version: 21.1Level: PTClassification code: 10059515Term: Non-small cell lung cancer metastatic Class: 100000004864CTIS2023-503376-24-00Merck Sharp & Dohme LLC625
进行中（未招募）
1 期
Clinical trial that compares MK-2870 with or without pembrolizumab to chemotherapy in people with breast cancer that cannot be surgically removed.Hormone receptor positive breast cancerMedDRA version: 23.0Level: PTClassification code: 10083234Term: Hormone receptor positive breast cancer Class: 100000004864CTIS2023-504918-29-00Merck Sharp & Dohme LLC1,249
尚未招募
3 期
Phase 3 study of MK-5684 versus alternative NHA in mCRPC Acronym: MK-5684-003D075 ProstateProstateD075PER-048-23Merck Sharp & Dohme LLC., (una subsidiaria de Merck & Co. Inc.)